May 24, 2007 (San Diego) — A recent study found that among patients in a psychiatric hospital, the atypical antipsychotic quetiapine (Seroquel, AstraZeneca), which is approved for schizophrenia and ...
Current Primary Outcome Measures •Percentage of Participants with Response (>=50 Percent improvement in MADRS total score from baseline) at Week 26 [ Time Frame: Week 26 ] -- Responders are defined as ...
An investigational drug did not significantly improve outcomes versus quetiapine extended release (Seroquel XR) as an adjunctive treatment in adults with major depressive disorder (MDD) and insomnia ...
PHILADELPHIA — Pimavanserin (Nuplazid) is noninferior to quetiapine in patients with Parkinson's disease (PD) psychosis at 56 days, results from a phase 3 trial showed. In the first prospective ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback